Phosphate ascorbate

Phosphate Ascorbate (Ascorbyl Phosphate): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Common Forms

Ascorbyl phosphate is a synthetic form of vitamin C and is found in different salt forms, most notably magnesium ascorbyl phosphate (MAP) and sodium ascorbyl phosphate (SAP). The parent compound from which all ascorbyl phosphates derive is L-ascorbic acid (vitamin C), which was first isolated in 1928 and subsequently identified as the long-sought antiscorbutic factor.

L-ascorbate-2-phosphate is a derivative of L-ascorbic acid, with a chemical formula C₆H₆O₉P, in which the carbon skeleton of L-ascorbic acid is bridged with a phosphate group at site 2. This phosphorylation at the 2-position is the defining structural feature of the entire class. In SAP, the cyclic ring contains a phosphate group at the second position. Sodium ascorbyl phosphate is a hydrophilic derivative of ascorbic acid with better stability compared to the parent compound.

The major commercial salt forms and their properties include:

• Sodium ascorbyl phosphate (SAP) — Sodium ascorbyl phosphate (SAP), with a phosphate group in the second position of the cyclic ring, is a synthesized derivative of ascorbic acid. Its synonyms include 2-Phospho-L-ascorbic Acid Trisodium Salt. Sodium ascorbyl phosphate functions as an antioxidant in cosmetic products and is used at concentrations ranging from 0.01% to 3%.
• Magnesium ascorbyl phosphate (MAP) — Also designated VC-PMG or Mg-L-ascorbyl-2-phosphate. Magnesium ascorbyl phosphate functions as an antioxidant in cosmetics and was reported being used at concentrations from 0.001% to 3%.
• Sodium calcium ascorbyl phosphate — This form is recognised by EFSA as a source of vitamin C used as a feed additive for all animal species.
• Calcium L-ascorbate-2-monophosphate / calcium L-ascorbate-2-triphosphate — These are used as stable vitamin C derivatives in animal feed, especially in the feed of aquaculture. In contrast, L-ascorbyl 2-phosphoric esters are an oxidation-stable and bioavailable form of vitamin C.
• Ascorbyl 2-polyphosphate (APP) — A protected form of vitamin C in which phosphorylation of the 2-hydroxyl group protects the 2,3-enediol of L-ascorbic acid against oxidation.

Ascorbic acid is one of the most important water-soluble micronutrients, widely used in pharmaceutical agents, cosmetic ingredients, and dietary supplements as a preservative, color-fixing agent, or antioxidant. However, it can be easily oxidized due to the existence of the unstable enediol in its structure, causing it to lose its biological activity, thereby limiting its application. Vitamin C is the least stable vitamin in foodstuffs because it is extremely reactive towards atmospheric oxygen, and it is known that ascorbic acid can be made more stable to oxygen and heat by converting it into suitable derivatives.

The main production method of L-ascorbate-2-phosphate is chemical synthesis, which primarily employs a group protection method. Despite a high yield, such methods require large energy consumption and cause a toxic effect on the environment. Biological preparation of L-ascorbate-2-phosphate has therefore attracted attention for its characteristics of stable product quality, safety, mild technological conditions, and high efficiency.

2. Natural Sources and Biological Context

Phosphate ascorbate as a class is not found in meaningful concentrations in whole foods; it is an industrially synthesized derivative. Its significance in biological systems is rooted in the broader essentiality of vitamin C. In invertebrates, primates, and many of the commonly cultured species of fish, the ability to synthesize L-ascorbic acid is absent. These animals lack the enzyme L-gulonolactone oxidase, which is required for synthesis of L-ascorbic acid, and require dietary vitamin C, which has a vast array of metabolic functions and is essential for normal growth and development.

Species that require a dietary source of vitamin C include humans, higher primates, guinea pigs, and birds. Without the required dietary vitamin C, body stores become depleted and the fatal deficiency disease scurvy manifests. Clinical scurvy is characterized by failure of wound healing, bleeding gums, bone and joint lesions, and other signs of connective tissue failure culminating in death.

3. Traditional and Historical Use

Phosphate ascorbate compounds are modern, industrially synthesized derivatives with no history of traditional botanical or folk medicinal use in their own right. They were developed in the twentieth century as a technological solution to the chemical instability of naturally occurring ascorbic acid. There is therefore no recorded traditional use of phosphate ascorbate in any culture or time period prior to its chemical synthesis.

The historical context that motivated their development lies in the long-documented consequences of vitamin C deficiency. Scurvy was a well-known disease of sailors, soldiers, and the poor in European and other cultures, treated empirically with citrus fruits, green vegetables, and in some traditions pine-needle infusions long before the chemistry of ascorbic acid was understood. L-ascorbic acid was first isolated in 1928 and subsequently identified as the long-sought antiscorbutic factor. Its chemical identity established, researchers subsequently worked to produce more stable derivatives that could withstand food processing, feed manufacturing, and formulation into topical preparations.

The impetus for developing phosphate esters intensified in the latter decades of the twentieth century with the expansion of industrial aquaculture. It is known that ascorbic acid can be made more stable to oxygen and heat by converting it into suitable derivatives, which is particularly important for the recently developed large-scale use of vitamin C in fish farming. Early published scientific work on ascorbyl phosphate salts for aquaculture appeared in the late 1980s, marking the beginning of systematic commercial use.

4. Key Constituents and Active Compounds

Ascorbyl phosphate compounds are themselves the active or prodrug entity; they have no additional secondary metabolites or botanical constituents. Their pharmacological activity is mediated entirely through two mechanisms: direct antioxidant activity in some forms, and liberation of free L-ascorbic acid following dephosphorylation by phosphatases.

4.1 Enzymatic Conversion to Ascorbic Acid

SAP has no direct antioxidant activity, but it is cleaved by the enzymes present in the skin to release active L-ascorbic acid. In SAP, the cyclic ring contains a phosphate group at the second position. SAP is cleaved by enzymes present in the skin to release active L-AA. The phosphate group at the second position protects the enediol structure from oxidation, making SAP more stable.

Ascorbic acid 2-phosphate (Asc 2-P) is stable under culture conditions and liberates ascorbic acid by the action of alkaline phosphatase (ALP) on the plasma membrane of various kinds of cells. This means that membrane-bound and extracellular phosphatases act as the enzyme gate, converting the stable prodrug form into the biologically active vitamin C molecule on demand.

Trisodium ascorbyl phosphate is the sodium salt of the monophosphate ester of ascorbic acid. It is a pro-vitamin, with greater stability in aqueous solution than ascorbic acid. Phosphatases in the skin act on trisodium ascorbyl phosphate to release ascorbic acid.

4.2 Antioxidant Mechanism

Once free ascorbic acid is released, it functions as one of the body's principal water-soluble antioxidants. As one of the most powerful antioxidants in the skin, vitamin C has been shown to protect against photoaging, ultraviolet-induced immunosuppression, and photocarcinogenesis. It also has an antiaging effect by increasing collagen synthesis, stabilizing collagen fibers, and decreasing collagen degradation. It decreases melanin formation, thereby reducing pigmentation.

4.3 Collagen Biosynthesis Co-factor Activity

Ascorbic acid — and its phosphate prodrug forms — function as essential co-factors in collagen biosynthesis. Proliferation of human skin fibroblasts was stimulated significantly by the presence of L-ascorbic acid 2-phosphate (Asc 2-P). The presence of Asc 2-P (0.1–1.0 mM) in the culture medium for 3 weeks enhanced the relative rate of collagen synthesis to total protein synthesis 2-fold as well as cell growth 4-fold. Supplementation of the medium with Asc 2-P also accelerated procollagen processing to collagen and deposition of collagen in the cell layer. Among the acidic glycosaminoglycans (GAG), another major component of extracellular matrix (ECM), deposition of sulfated forms was increased by the additive.

4.4 Melanogenesis Inhibition

A 2019 mechanistic study demonstrated that L-ascorbic acid, magnesium ascorbyl phosphate, and 3-O-ethyl L-ascorbic acid all suppress tyrosinase activity by acidifying the melanocyte cytoplasm — tyrosinase activity drops sharply in acidic environments. When researchers neutralized intracellular pH with ammonium chloride or concanamycin A, tyrosinase activity rebounded, proving the inhibition is pH-driven rather than transcriptional.

Treatment of melanocytes with vitamin C or its derivatives, magnesium ascorbyl phosphate (MAP) and 3-O-ethyl-L-ascorbic acid (AAE), resulted in significant decreases in tyrosinase activity and melanin content and in the levels of intracellular reactive oxygen species (ROS), indicating that VC and its derivatives possess antimelanogenic and antioxidative activities. Western blotting analysis indicated that VC, MAP, and AAE exert their antimelanogenic activity by inhibiting tyrosinase activity rather than by downregulating the expression of melanogenic proteins such as tyrosinase, premelanosome protein 17 (Pmel17), and microphthalmia-associated transcription factor (MITF).

4.5 Anti-Inflammatory Properties

Magnesium ascorbyl phosphate (MAP) is a stable precursor of vitamin C that achieves a constant delivery of vitamin C into the skin and has antioxidative effects. Studies have been performed to evaluate the effect of MAP on the expression of inflammatory biomarkers in cultured sebocytes.

4.6 Stability Advantage

Phosphorylation of the 2-hydroxyl group protects the 2,3-enediol of L-ascorbic acid against oxidation. Stability of ascorbyl polyphosphate (APP) in pelleted feeds at 25°C or 40°C was up to 83 times or 45 times greater than that of ascorbic acid, respectively. Sodium ascorbyl phosphate is a hydrophilic derivative of ascorbic acid with better stability compared to the parent compound. However, sodium ascorbyl phosphate is not as stable in solution as it is in the solid state, and it has been found to degrade, with accompanying discoloration, under the influence of different conditions.

5. Scientific Evidence by Area of Use

5.1 Acne Vulgaris

This is the area with the most direct human clinical evidence for sodium ascorbyl phosphate specifically.

Antimicrobial activity (in vitro): 1% SAP has a strong antimicrobial effect with a log reduction of 5 after 8 hours on P. acnes in a time-kill study.

Sebum oxidation prevention (human, in vivo): 1% SAP has a strong antimicrobial effect on P. acnes, and in a human in vivo study with 20 subjects, an SAP O/W formulation significantly prevented UVA-induced sebum oxidation by up to 40%.

Open-label clinical study (60 subjects, 12 weeks): Sodium ascorbyl phosphate, a strong antioxidant, was used at a concentration of 5% in the production of a lotion applied topically for 12 weeks in an open human study group, and was shown to significantly reduce lipid peroxidation and improve acne.

Randomized, double-blind, controlled trial (5% SAP lotion): A study demonstrated that 5% sodium L-ascorbyl-2-phosphate is efficacious as monotherapy for the treatment of acne. APS 5% lotion offers a novel addition to the current acne armamentarium. APS 5% lotion demonstrated statistically significant improvement when compared to vehicle in all of the parameters measured, including Investigator's Global Assessment Score, Subjects' Global Assessment Score, and lesion counts.

Comparison studies (open-label, multi-center): A multicenter, open-label clinical trial compared the efficacy and tolerability of APS versus 1% clindamycin phosphate lotion in the treatment of facial acne vulgaris. APS demonstrated efficacy in the topical treatment of acne vulgaris and superiority to the comparator for this indication.

Comparison with adapalene (open-label, 60 patients, 12 weeks): Sixty patients were randomized to apply either APS or adapalene 0.1% gel for 12 weeks. Among 53 patients who completed the study, APS treatment was consistently superior to adapalene in inflammatory acne lesion reduction at any study period. The overall study results showed the superior efficacy and safety of APS 5% lotion compared with that of adapalene 0.1% gel in the treatment of acne vulgaris.

Combination with retinol (randomized, double-blind): Randomized and double-blind studies on the comparison of efficacies of topical formulations containing 5% SAP and 0.2% retinol, separately as well as in combination, were conducted. SAP reduced the inflammatory lesion by 20.14% and 48.82% within 4 and 8 weeks respectively. Retinol application slightly improved treatment efficacy, reducing lesions by 21.79% and 49.50% after 4 and 8 weeks respectively. The combination treatment significantly reduced the inflammatory lesion by 29.28% after 4 weeks and 63.10% after 8 weeks of application.

Evidence strength: Moderate. Multiple clinical trials exist at the 5% concentration, including at least one randomized double-blind controlled trial. Studies are generally small to moderate in size, and most lack long-term follow-up. The open-label design of several studies is a methodological limitation.

5.2 Skin Hyperpigmentation and Melasma

In vitro and human in vivo (MAP, 10% cream): A study examined the effect on pigmentation of magnesium-L-ascorbyl-2-phosphate (VC-PMG), a stable derivative of ascorbic acid. Percutaneous absorption was examined in dermatomed human skin, and its effect on melanin production by mammalian tyrosinase and human melanoma cells in culture was measured. A 10% VC-PMG cream was applied to patients. VC-PMG suppressed melanin formation by tyrosinase and melanoma cells. In situ experiments demonstrated that VC-PMG cream was absorbed into the epidermis and that 1.6% remained 48 hours after application. The lightening effect was significant in 19 of 34 patients with chloasma or senile freckles and in 3 of 25 patients with normal skin. VC-PMG was effective in reducing skin hyperpigmentation in some patients.

Clinical improvement (in vivo, MAP 10%): Kameyama et al. demonstrated a clinical improvement in an in vivo study in melasma and senile freckles when a 10% topical formulation of ascorbyl phosphate and magnesium was applied. It is also a free radical scavenger that is photoprotective and increases collagen production under laboratory test conditions.

Split-face clinical study (MAP ethosomal vs. niosomal gel, melasma patients): A comparative split-face clinical study was done between ethosomal and niosomal MAP formulations for melasma treatment. The optimized ethosomal and niosomal gels showed comparable controlled permeation and higher skin retention. Magnesium ascorbyl phosphate ethosomal gel showed clinically and statistically significant melanin level decrease after one month, while MAP niosomal gel showed clinically and statistically significant melanin level decrease after six months.

Ascorbic acid in magnesium ascorbyl-2-phosphate (MAP) cream form is considered by some researchers to be more effective than vitamin C in its natural form, attributing this to its better stability and esterified structure.

Evidence strength: Preliminary to moderate. Human data is available but largely from uncontrolled or small studies. The mechanistic evidence for tyrosinase inhibition is well characterized in vitro. Larger, fully blinded, placebo-controlled trials are lacking.

5.3 Photoprotection and Anti-Photoaging

Animal data (MAP, UVB protection): The protective effect of magnesium-L-ascorbyl-2-phosphate (MAP) on cutaneous photodamage such as lipid peroxidation and inflammation induced by UVB exposure (290–320 nm) was investigated using hairless mice. When MAP was administered intraperitoneally at a dose of 100 mg of ascorbic acid per kg body weight immediately before irradiation, the expected increases in thiobarbituric acid reactive substance (TBARS) formation in skin and serum sialic acid — indices of lipid peroxidation and inflammatory reaction, respectively — were significantly reduced.

Elmore (2005) reported evidence that magnesium ascorbyl phosphate administered immediately after exposure in hairless mice significantly delayed skin-tumor formation and hyperplasia induced by chronic exposure to UVR, and that ascorbic acid applied to mice and pig skin prior to UVR reduced skin-cancer-related damage. A limitation of these studies is that most were conducted on animal or human in vitro models. Human in vivo studies are preferred for studying the utility of antioxidant supplementation in humans.

Anti-wrinkle human clinical study (5% SAP emulgel): Formulations containing ascorbic acid and/or SAP both improved elasticity and wrinkles of the skin almost by the same extent, and it is necessary to add antioxidant stabilizing agents to both preparations to reach a desired stability.

Magnesium-L-ascorbyl-2-phosphate, described as the most stable and preferred ascorbyl ester, generates protection against UVB radiation-induced lipid peroxidation in hairless mice. In vitro studies show evidence that magnesium ascorbyl phosphate penetrates the epidermis and forms ascorbic acid through the dephosphorylation of the cell membrane.

Evidence strength: Predominantly animal and in vitro. Human clinical evidence is limited and largely assessed as part of broader vitamin C derivative reviews rather than via dedicated large randomized controlled trials specifically for phosphate ascorbate forms.

5.4 Collagen Synthesis and Bone/Connective Tissue Biology

This is primarily a cell culture and tissue-engineering area. To investigate the effect of ascorbic acid (AsA) and ascorbic acid 2-phosphate (Asc 2-P), a long-acting vitamin C derivative, on the growth and differentiation of human osteoblast-like cells, MG-63 cells were supplemented with various concentrations (0.25 to 1 mM) of these factors. Asc 2-P significantly stimulated nascent cell growth at all concentrations in the presence of fetal bovine serum (FBS). On the other hand, AsA showed a growth repressive effect depending on its concentration. Asc 2-P also increased expression of osteoblast differentiation markers, such as collagen synthesis and alkaline phosphatase (ALP) activity.

A phosphate derivative of ascorbic acid, ascorbic acid 2-phosphate (Asc 2-P), had a cofactor activity for collagen biosynthesis by human fibroblasts in culture.

In the context of mesenchymal stem cells (MSCs): MSCs were cultured in media containing various concentrations (0–500 μM) of L-ascorbate-2-phosphate (Asc-2-P) for 2 weeks, following which they were differentiated into adipocytes and osteoblasts. Ascorbic acid stimulated ECM secretion (collagen and glycosaminoglycan) and cell proliferation.

In tissue engineering applications, ascorbic acid 2-phosphate (A2P), a more stable form of ascorbic acid, has attracted interest in tissue engineering. The utility of A2P has been especially recognized in bone tissue engineering; however, in gynecological applications, increased collagen production is also highly desirable.

Evidence strength: Strong in vitro evidence for collagen synthesis stimulation. No human clinical trials demonstrate this specific effect of phosphate ascorbate alone on human collagen production in vivo.

5.5 Aquaculture and Animal Nutrition (Feed Additive)

This is a well-established application supported by decades of study. The rate of L-ascorbic acid degradation in feeds is high and is influenced by many factors. More stable derivatives of vitamin C, which can better resist oxidation, have become available on the market for aquafeeds. Several attempts have been made to improve the stability of ascorbic acid, such as coatings or derivation (ascorbyl polyphosphate). The biological activity of the latter form has been confirmed in channel catfish as well as in rainbow trout.

To overcome the lability of vitamin C, the efficacy of Mg-L-ascorbyl-2-phosphate (MAP), a relatively stable derivative, was examined. Groups of juvenile Penaeus japonicus shrimp were fed five different test diets containing different amounts of MAP for 100 days. Normal growth was observed in test groups fed diets containing 1,078, 430, and 215 mg MAP per kg, whereas mass mortality occurred in populations fed diets containing 43 and 0 mg MAP per kg. The dead shrimp exhibited blackened lesions underneath the exoskeleton.

Repeated measurements of remaining L-ascorbic acid and MAP demonstrated that MAP was significantly more stable than L-ascorbic acid and was less prone to leaching in sea water.

The EFSA FEEDAP Panel assessed the application for renewal of authorisation of ascorbic acid, sodium ascorbate, calcium ascorbate, ascorbyl palmitate, sodium calcium ascorbyl phosphate, and sodium ascorbyl phosphate as sources of vitamin C as feed additives for all animal species. The applicants provided data demonstrating that the additives currently in the market comply with the conditions of authorisation. The FEEDAP Panel concluded that the additives remain safe for the target species, consumers, and the environment.

5.6 Wound Healing and Tissue Engineering

Embedding ascorbic acid or its derivatives directly into scaffolds has emerged as an interesting idea for tissue engineering, allowing ascorbic acid release from the scaffold. Previously, A2P-embedded porous polylactide (PLA) and poly-L-lactide-co-ε-caprolactone (PLCL) scaffolds have been studied for pelvic organ prolapse and urological applications with potentially encouraging results.

Evidence strength: Preclinical only. These findings are from in vitro cell culture and animal experiments; no controlled human trials exist for this application.

6. Body Systems and Health Areas

• Integumentary system (skin): The primary area of documented human application, encompassing antioxidant protection, anti-acne, anti-pigmentation, anti-photoaging, and wound-healing support.
• Musculoskeletal system (connective tissue and bone): Application of Asc 2-P as a supplement to cultures of human osteoblast-like MG-63 cells stimulated collagen synthesis and differentiation, indicated by elevated alkaline phosphatase activity, as well as cell proliferation.
• Immune and redox defence systems: As one of the most powerful antioxidants in the skin, vitamin C (delivered via its phosphate prodrugs) has been shown to protect against photoaging, ultraviolet-induced immunosuppression, and photocarcinogenesis.
• Extracellular matrix biology: Proliferation and collagen synthesis of stellate cells are stimulated by the long-acting vitamin C derivative, L-ascorbic acid 2-phosphate, indicating that morphology, proliferation, and collagen metabolism are regulated by extracellular matrix and modulated further by L-ascorbic acid 2-phosphate.

7. Dosage Forms and Reported Dosages

Phosphate ascorbate is not typically used as an oral dietary supplement in humans in the same way as plain vitamin C. Its primary documented human use is topical. The following dosages and concentrations are those reported in cited studies:

• Topical SAP for acne (human clinical trials): Sodium L-ascorbyl-2-phosphate (APS) is a stable vitamin C derivative; studies evaluated the efficacy and safety of APS 5% lotion for the treatment of acne.
• Topical SAP for anti-wrinkle (human volunteers): 5% SAP emulgel preparations have been evaluated in clinical studies alongside 5% ascorbic acid preparations. Formulations containing ascorbic acid and/or SAP both improved elasticity and wrinkles of the skin to a similar extent.
• Topical SAP for sebum oxidation prevention (human, 20 subjects): An SAP O/W formulation significantly prevented UVA-induced sebum oxidation up to 40%.
• Topical MAP for hyperpigmentation/melasma (human in vivo): A 10% VC-PMG cream was applied to patients in the key published clinical series on MAP and pigmentation.
• Cosmetic-grade topical concentrations (general): Sodium ascorbyl phosphate functions as an antioxidant in cosmetic products at concentrations ranging from 0.01% to 3%. Magnesium ascorbyl phosphate functions as an antioxidant in cosmetics at concentrations from 0.001% to 3%.
• Aquaculture feed (shrimp): Groups of juvenile Penaeus japonicus were fed five different test diets containing different amounts of MAP for 100 days. Normal growth was observed on test groups fed diets containing 1,078, 430, and 215 mg MAP per kg.
• Cell culture (in vitro, collagen synthesis): Asc 2-P at 0.1–1.0 mM in culture medium for 3 weeks was the range used in skin fibroblast experiments demonstrating enhanced collagen synthesis.

8. Safety Considerations and Notable Interactions

8.1 Regulatory Safety Status

Ascorbic acid is a generally recognized as safe (GRAS) substance for use as a chemical preservative in foods and as a nutrient and/or dietary supplement. In 2005, the Cosmetic Ingredient Review (CIR) Expert Panel concluded that L-ascorbic acid, ascorbyl phosphates, and ascorbates are safe as used in cosmetics.

The EFSA FEEDAP Panel concluded that the additives remain safe for target species, consumers, and the environment. Regarding user safety, ascorbic acid and sodium ascorbyl phosphate are not irritant to the skin or eyes and are not dermal sensitisers.

8.2 Skin Tolerability

One of the cited advantages of phosphate ascorbate forms over free ascorbic acid in topical applications is the absence of low-pH irritation. Magnesium ascorbyl phosphate appears to have the same potential as vitamin C to boost skin collagen synthesis but is effective at significantly lower concentrations. Most vitamin C formulas are highly acidic and therefore produce exfoliation, so magnesium ascorbyl phosphate is a preferred ascorbic acid derivative for use in compositions, particularly those for individuals with sensitive skin and those wishing to avoid exfoliating effects.

No deaths or signs of systemic toxicity were observed in safety assessments of sodium ascorbyl phosphate in water. The CIR panel review found pregnant mice and rats given daily oral doses of ascorbic acid up to 1000 mg/kg body weight showed no indications of adult-toxic, teratogenic, or fetotoxic effects.

8.3 Genotoxicity

Ascorbic acid and sodium ascorbate were not genotoxic in several bacterial and mammalian test systems, consistent with the antioxidant properties of these chemicals.

8.4 Skin Tumor Protection (Animal Evidence)

Magnesium ascorbyl phosphate administration immediately after exposure in hairless mice significantly delayed skin tumor formation and hyperplasia induced by chronic exposure to UV radiation. Evidence of magnesium ascorbyl phosphate's toxicity was obtained at ingested levels significantly higher than what one would encounter in typical cosmetic products with magnesium ascorbyl phosphate or ascorbic acid.

8.5 Formulation and Stability Considerations

Sodium ascorbyl phosphate is a hydrophilic derivative of ascorbic acid with better stability compared to the parent compound. However, sodium ascorbyl phosphate is not as stable in solution as it is in the solid state, and it has been found to degrade, with accompanying discoloration, under the influence of different conditions. Studies have shown that concentration, temperature, pH, light, oxygen exposure, and the presence of metal ions all affect its stability in solution.

8.6 Conversion Efficiency and Bioavailability Considerations

The efficacy of phosphate ascorbate forms is inherently dependent on enzymatic dephosphorylation at the site of application or metabolism. In vitro studies show evidence that magnesium ascorbyl phosphate penetrates the epidermis and forms ascorbic acid through the dephosphorylation of the cell membrane. The rate and completeness of this conversion may vary between individuals and application sites, which may limit predictability of clinical response compared to free ascorbic acid, though the stability advantage in formulation typically offsets this concern in practice. Clinical studies on the efficacy of topical formulations of vitamin C remain limited, and the challenge lies in finding the most stable and permeable formulation in achieving the optimal results.

References

• PubChem: Ascorbate-2-phosphate | CID 54679073 — National Center for Biotechnology Information
• Stability of sodium ascorbyl phosphate in the water-glycerol system — Journal of Pharmaceutical and Biomedical Analysis (2020)
• Ascorbyl phosphate: Uses, Interactions, Mechanism of Action — DrugBank
• EFSA FEEDAP Panel Assessment of Ascorbic Acid and Ascorbyl Phosphate Feed Additives — EFSA Journal (2025)
• L-ascorbic acid 2-phosphate stimulates collagen accumulation, cell proliferation, and formation of a three-dimensional tissue-like substance by skin fibroblasts — Journal of Cellular Physiology (1989)
• Effects of ascorbic acid and ascorbic acid 2-phosphate on the proliferation and differentiation of human osteoblast-like cells — Bone (2004)
• Histopathological, morphometric and stereological studies of ascorbic acid and magnesium ascorbyl phosphate in a skin care formulation — PubMed (2008)
• Magnesium ascorbyl phosphate vesicular carriers for topical delivery; clinical assessment in melasma patients — Drug Delivery (2022)
• Protective effect of magnesium-L-ascorbyl-2-phosphate against skin damage induced by UVB irradiation — PubMed (1996)
• Magnesium Ascorbyl Phosphate Regulates the Expression of Inflammatory Biomarkers in Cultured Sebocytes — PubMed (2015)
• Sodium ascorbyl phosphate shows in vitro and in vivo efficacy in the prevention and treatment of acne vulgaris — International Journal of Cosmetic Science (2005)
• Sodium L-ascorbyl-2-phosphate 5% lotion for the treatment of acne vulgaris: a randomized, double-blind, controlled trial — Journal of Cosmetic Dermatology (2010)
• Comparison of clinical efficacies of sodium ascorbyl phosphate, retinol and their combination in acne treatment — ResearchGate
• Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo — Journal of the American Academy of Dermatology (1996)
• Intramelanocytic Acidification Plays a Role in the Antimelanogenic and Antioxidative Properties of Vitamin C and Its Derivatives — PMC (2019)
• Topical Vitamin C and the Skin: Mechanisms of Action and Clinical Applications — PubMed (2017)
• Comparative physicochemical stability and clinical anti-wrinkle efficacy of transdermal emulgel preparations of 5% sodium ascorbyl phosphate and or ascorbic acid on human volunteers — PubMed (2020)
• Ascorbic Acid in Skin Health — Cosmetics (2019)
• Evidence-Based Utility of Adjunct Antioxidant Supplementation for the Prevention and Treatment of Dermatologic Diseases — PMC (2023)
• Final Report of the Safety Assessment of L-Ascorbic Acid, Magnesium Ascorbyl Phosphate, Sodium Ascorbyl Phosphate as Used in Cosmetics — International Journal of Toxicology / CIR (2005)
• Safety Assessment of Ascorbic Acid and Ascorbates as Used in Cosmetics — Cosmetic Ingredient Review (CIR)
• Use of Mg-L-Ascorbyl-2-Phosphate as a Vitamin C Source in Shrimp Diets — Journal of the World Aquaculture Society (1988)
• Polyphosphorylated L-ascorbic Acid: A Stable Form of Vitamin C for Aquaculture Feeds — Journal of the World Aquaculture Society (1989)
• Ascorbic acid availability from ascorbyl 2-polyphosphate and ascorbyl 2-sulfate in sea bass — Aquaculture (1997)
• Ascorbic Acid 2-Phosphate Releasing Supercritically Foamed Porous PLCL Scaffold Enhances Collagen Production of Human Vaginal Stromal Cells — PMC (2024)
• Synthesis and efficacy of tetraacetyl vitamin C ester: alternative to traditional vitamin C in aquafeeds — PMC (2026)